Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Small molecule anionophores promote transmembrane anion permeation matching CFTR activity.

Hernando E, Capurro V, Cossu C, Fiore M, García-Valverde M, Soto-Cerrato V, Pérez-Tomás R, Moran O, Zegarra-Moran O, Quesada R.

Sci Rep. 2018 Feb 8;8(1):2608. doi: 10.1038/s41598-018-20708-3.

2.

In vitro recapitulation of the site-specific editing (to wild-type) of mutant IDS mRNA transcripts, and the characterization of IDS protein translated from the edited mRNAs.

Lualdi S, Del Zotto G, Zegarra-Moran O, Pedemonte N, Corsolini F, Bruschi M, Tomati V, Amico G, Candiano G, Dardis A, Cooper DN, Filocamo M.

Hum Mutat. 2017 Jul;38(7):849-862. doi: 10.1002/humu.23243. Epub 2017 May 22.

PMID:
28477385
3.

CFTR pharmacology.

Zegarra-Moran O, Galietta LJ.

Cell Mol Life Sci. 2017 Jan;74(1):117-128. doi: 10.1007/s00018-016-2392-x. Epub 2016 Oct 4. Review.

PMID:
27704174
4.

Pharmacological analysis of epithelial chloride secretion mechanisms in adult murine airways.

Gianotti A, Ferrera L, Philp AR, Caci E, Zegarra-Moran O, Galietta LJ, Flores CA.

Eur J Pharmacol. 2016 Jun 15;781:100-8. doi: 10.1016/j.ejphar.2016.04.007. Epub 2016 Apr 7.

PMID:
27063443
5.

Evaluation of a systems biology approach to identify pharmacological correctors of the mutant CFTR chloride channel.

Pesce E, Gorrieri G, Sirci F, Napolitano F, Carrella D, Caci E, Tomati V, Zegarra-Moran O, di Bernardo D, Galietta LJ.

J Cyst Fibros. 2016 Jul;15(4):425-35. doi: 10.1016/j.jcf.2016.02.009. Epub 2016 Mar 10.

6.

Structure of wild type and mutant F508del CFTR: A small-angle X-ray scattering study of the protein-detergent complexes.

Pollock NL, Satriano L, Zegarra-Moran O, Ford RC, Moran O.

J Struct Biol. 2016 Apr;194(1):102-11. doi: 10.1016/j.jsb.2016.02.004. Epub 2016 Feb 3.

PMID:
26850167
7.

Rheological Properties of Cystic Fibrosis Bronchial Secretion and in Vitro Drug Permeation Study: The Effect of Sodium Bicarbonate.

Stigliani M, Manniello MD, Zegarra-Moran O, Galietta L, Minicucci L, Casciaro R, Garofalo E, Incarnato L, Aquino RP, Del Gaudio P, Russo P.

J Aerosol Med Pulm Drug Deliv. 2016 Aug;29(4):337-45. doi: 10.1089/jamp.2015.1228. Epub 2016 Jan 7.

PMID:
26741302
8.

Pharmacological rescue of mutant CFTR protein improves the viscoelastic properties of CF mucus.

Gianotti A, Capurro V, Scudieri P, Galietta LJ, Moran O, Zegarra-Moran O.

J Cyst Fibros. 2016 May;15(3):295-301. doi: 10.1016/j.jcf.2015.11.003. Epub 2015 Dec 9.

9.

Synthesis and structure-activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis.

Pesce E, Bellotti M, Liessi N, Guariento S, Damonte G, Cichero E, Galatini A, Salis A, Gianotti A, Pedemonte N, Zegarra-Moran O, Fossa P, Galietta LJ, Millo E.

Eur J Med Chem. 2015 Jun 24;99:14-35. doi: 10.1016/j.ejmech.2015.05.030. Epub 2015 May 28.

PMID:
26041577
10.

Functional analysis of acid-activated Cl⁻ channels: properties and mechanisms of regulation.

Capurro V, Gianotti A, Caci E, Ravazzolo R, Galietta LJ, Zegarra-Moran O.

Biochim Biophys Acta. 2015 Jan;1848(1 Pt A):105-14.

11.

Functional and pharmacological induced structural changes of the cystic fibrosis transmembrane conductance regulator in the membrane solved using SAXS.

Baroni D, Zegarra-Moran O, Moran O.

Cell Mol Life Sci. 2015 Apr;72(7):1363-75. doi: 10.1007/s00018-014-1747-4. Epub 2014 Oct 2.

PMID:
25274064
12.

Direct interaction of a CFTR potentiator and a CFTR corrector with phospholipid bilayers.

Baroni D, Zegarra-Moran O, Svensson A, Moran O.

Eur Biophys J. 2014 Jul;43(6-7):341-6. doi: 10.1007/s00249-014-0956-y. Epub 2014 Apr 26.

PMID:
24771136
13.

Epithelial sodium channel silencing as a strategy to correct the airway surface fluid deficit in cystic fibrosis.

Gianotti A, Melani R, Caci E, Sondo E, Ravazzolo R, Galietta LJ, Zegarra-Moran O.

Am J Respir Cell Mol Biol. 2013 Sep;49(3):445-52. doi: 10.1165/rcmb.2012-0408OC.

PMID:
23600628
14.

Association of TMEM16A chloride channel overexpression with airway goblet cell metaplasia.

Scudieri P, Caci E, Bruno S, Ferrera L, Schiavon M, Sondo E, Tomati V, Gianotti A, Zegarra-Moran O, Pedemonte N, Rea F, Ravazzolo R, Galietta LJ.

J Physiol. 2012 Dec 1;590(23):6141-55. doi: 10.1113/jphysiol.2012.240838. Epub 2012 Sep 17.

15.

Ca2+-activated Cl- channels.

Ferrera L, Zegarra-Moran O, Galietta LJ.

Compr Physiol. 2011 Oct;1(4):2155-74. doi: 10.1002/cphy.c110017. Review.

PMID:
23733701
16.

Pharmacological therapy for cystic fibrosis: from bench to bedside.

Becq F, Mall MA, Sheppard DN, Conese M, Zegarra-Moran O.

J Cyst Fibros. 2011 Jun;10 Suppl 2:S129-45. doi: 10.1016/S1569-1993(11)60018-0. Review.

17.

A minimal isoform of the TMEM16A protein associated with chloride channel activity.

Ferrera L, Scudieri P, Sondo E, Caputo A, Caci E, Zegarra-Moran O, Ravazzolo R, Galietta LJ.

Biochim Biophys Acta. 2011 Sep;1808(9):2214-23. doi: 10.1016/j.bbamem.2011.05.017. Epub 2011 May 30.

18.

High-throughput screening of libraries of compounds to identify CFTR modulators.

Pedemonte N, Zegarra-Moran O, Galietta LJ.

Methods Mol Biol. 2011;741:13-21. doi: 10.1007/978-1-61779-117-8_2.

PMID:
21594775
19.

Dual activity of aminoarylthiazoles on the trafficking and gating defects of the cystic fibrosis transmembrane conductance regulator chloride channel caused by cystic fibrosis mutations.

Pedemonte N, Tomati V, Sondo E, Caci E, Millo E, Armirotti A, Damonte G, Zegarra-Moran O, Galietta LJ.

J Biol Chem. 2011 Apr 29;286(17):15215-26. doi: 10.1074/jbc.M110.184267. Epub 2011 Mar 7.

20.

Modulation of cystic fibrosis transmembrane conductance regulator (CFTR) activity and genistein binding by cytosolic pH.

Melani R, Tomati V, Galietta LJ, Zegarra-Moran O.

J Biol Chem. 2010 Dec 31;285(53):41591-6. doi: 10.1074/jbc.M110.166850. Epub 2010 Oct 25.

21.

CFTR expression and activity from the human CFTR locus in BAC vectors, with regulatory regions, isolated by a single-step procedure.

Auriche C, Di Domenico EG, Pierandrei S, Lucarelli M, Castellani S, Conese M, Melani R, Zegarra-Moran O, Ascenzioni F.

Gene Ther. 2010 Nov;17(11):1341-54. doi: 10.1038/gt.2010.89. Epub 2010 Jun 10.

PMID:
20535216
22.

Regulation of TMEM16A chloride channel properties by alternative splicing.

Ferrera L, Caputo A, Ubby I, Bussani E, Zegarra-Moran O, Ravazzolo R, Pagani F, Galietta LJ.

J Biol Chem. 2009 Nov 27;284(48):33360-8. doi: 10.1074/jbc.M109.046607. Epub 2009 Oct 9.

23.

Mutation-specific potency and efficacy of cystic fibrosis transmembrane conductance regulator chloride channel potentiators.

Caputo A, Hinzpeter A, Caci E, Pedemonte N, Arous N, Di Duca M, Zegarra-Moran O, Fanen P, Galietta LJ.

J Pharmacol Exp Ther. 2009 Sep;330(3):783-91. doi: 10.1124/jpet.109.154146. Epub 2009 Jun 2.

24.

Analysis of ion transport in the airway epithelium using RNA interference.

Melani R, Galietta LJ, Zegarra Moran O.

Curr Opin Mol Ther. 2009 Jun;11(3):282-91. Review.

PMID:
19479661
25.

On the measurement of the functional properties of the CFTR.

Moran O, Zegarra-Moran O.

J Cyst Fibros. 2008 Nov;7(6):483-94. doi: 10.1016/j.jcf.2008.05.003. Epub 2008 Sep 25. Review.

26.

TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity.

Caputo A, Caci E, Ferrera L, Pedemonte N, Barsanti C, Sondo E, Pfeffer U, Ravazzolo R, Zegarra-Moran O, Galietta LJ.

Science. 2008 Oct 24;322(5901):590-4. doi: 10.1126/science.1163518. Epub 2008 Sep 4.

27.

Epithelial sodium channel inhibition in primary human bronchial epithelia by transfected siRNA.

Caci E, Melani R, Pedemonte N, Yueksekdag G, Ravazzolo R, Rosenecker J, Galietta LJ, Zegarra-Moran O.

Am J Respir Cell Mol Biol. 2009 Feb;40(2):211-6. doi: 10.1165/rcmb.2007-0456OC. Epub 2008 Aug 21.

PMID:
18723440
28.

Nanomolar CFTR inhibition by pore-occluding divalent polyethylene glycol-malonic acid hydrazides.

Sonawane ND, Zhao D, Zegarra-Moran O, Galietta LJ, Verkman AS.

Chem Biol. 2008 Jul 21;15(7):718-28. doi: 10.1016/j.chembiol.2008.05.015.

29.

Evidence for direct CFTR inhibition by CFTR(inh)-172 based on Arg347 mutagenesis.

Caci E, Caputo A, Hinzpeter A, Arous N, Fanen P, Sonawane N, Verkman AS, Ravazzolo R, Zegarra-Moran O, Galietta LJ.

Biochem J. 2008 Jul 1;413(1):135-42. doi: 10.1042/BJ20080029.

PMID:
18366345
30.

Alpha-aminoazaheterocyclic-methylglyoxal adducts do not inhibit cystic fibrosis transmembrane conductance regulator chloride channel activity.

Sonawane ND, Zegarra-Moran O, Namkung W, Galietta LJ, Verkman AS.

J Pharmacol Exp Ther. 2008 May;325(2):529-35. doi: 10.1124/jpet.107.132357. Epub 2008 Feb 13.

PMID:
18272811
31.

Lectin conjugates as potent, nonabsorbable CFTR inhibitors for reducing intestinal fluid secretion in cholera.

Sonawane ND, Zhao D, Zegarra-Moran O, Galietta LJ, Verkman AS.

Gastroenterology. 2007 Apr;132(4):1234-44. Epub 2007 Feb 7.

PMID:
17408659
32.

Thiocyanate transport in resting and IL-4-stimulated human bronchial epithelial cells: role of pendrin and anion channels.

Pedemonte N, Caci E, Sondo E, Caputo A, Rhoden K, Pfeffer U, Di Candia M, Bandettini R, Ravazzolo R, Zegarra-Moran O, Galietta LJ.

J Immunol. 2007 Apr 15;178(8):5144-53.

33.

Block of CFTR-dependent chloride currents by inhibitors of multidrug resistance-associated proteins.

Diena T, Melani R, Caci E, Pedemonte N, Sondo E, Zegarra-Moran O, Galietta LJ.

Eur J Pharmacol. 2007 Apr 10;560(2-3):127-31. Epub 2007 Feb 3.

34.
35.

Proteomic analysis of the airway surface liquid: modulation by proinflammatory cytokines.

Candiano G, Bruschi M, Pedemonte N, Musante L, Ravazzolo R, Liberatori S, Bini L, Galietta LJ, Zegarra-Moran O.

Am J Physiol Lung Cell Mol Physiol. 2007 Jan;292(1):L185-98.

36.

Antihypertensive 1,4-dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations.

Pedemonte N, Diena T, Caci E, Nieddu E, Mazzei M, Ravazzolo R, Zegarra-Moran O, Galietta LJ.

Mol Pharmacol. 2005 Dec;68(6):1736-46. Epub 2005 Sep 8.

PMID:
16150931
37.

Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening.

Pedemonte N, Lukacs GL, Du K, Caci E, Zegarra-Moran O, Galietta LJ, Verkman AS.

J Clin Invest. 2005 Sep;115(9):2564-71. Epub 2005 Aug 25.

38.

Effect of inflammatory stimuli on airway ion transport.

Galietta LJ, Folli C, Caci E, Pedemonte N, Taddei A, Ravazzolo R, Zegarra-Moran O.

Proc Am Thorac Soc. 2004;1(1):62-5. Review.

PMID:
16113414
39.

Gelsolin secretion in interleukin-4-treated bronchial epithelia and in asthmatic airways.

Candiano G, Bruschi M, Pedemonte N, Caci E, Liberatori S, Bini L, Pellegrini C, Viganò M, O'Connor BJ, Lee TH, Galietta LJ, Zegarra-Moran O.

Am J Respir Crit Care Med. 2005 Nov 1;172(9):1090-6. Epub 2005 Aug 11.

PMID:
16100010
40.
41.

Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating.

Pedemonte N, Sonawane ND, Taddei A, Hu J, Zegarra-Moran O, Suen YF, Robins LI, Dicus CW, Willenbring D, Nantz MH, Kurth MJ, Galietta LJ, Verkman AS.

Mol Pharmacol. 2005 May;67(5):1797-807. Epub 2005 Feb 18.

PMID:
15722457
42.

Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains.

Moran O, Galietta LJ, Zegarra-Moran O.

Cell Mol Life Sci. 2005 Feb;62(4):446-60.

PMID:
15719171
43.

Double mechanism for apical tryptophan depletion in polarized human bronchial epithelium.

Zegarra-Moran O, Folli C, Manzari B, Ravazzolo R, Varesio L, Galietta LJ.

J Immunol. 2004 Jul 1;173(1):542-9.

44.

Altered channel gating mechanism for CFTR inhibition by a high-affinity thiazolidinone blocker.

Taddei A, Folli C, Zegarra-Moran O, Fanen P, Verkman AS, Galietta LJ.

FEBS Lett. 2004 Jan 30;558(1-3):52-6.

45.

CFTR activation in human bronchial epithelial cells by novel benzoflavone and benzimidazolone compounds.

Caci E, Folli C, Zegarra-Moran O, Ma T, Springsteel MF, Sammelson RE, Nantz MH, Kurth MJ, Verkman AS, Galietta LJ.

Am J Physiol Lung Cell Mol Physiol. 2003 Jul;285(1):L180-8. Epub 2003 Mar 21.

46.

Correction of G551D-CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB-07.

Zegarra-Moran O, Romio L, Folli C, Caci E, Becq F, Vierfond JM, Mettey Y, Cabrini G, Fanen P, Galietta LJ.

Br J Pharmacol. 2002 Oct;137(4):504-12.

47.

Functional human CFTR produced by a stable minichromosome.

Auriche C, Carpani D, Conese M, Caci E, Zegarra-Moran O, Donini P, Ascenzioni F.

EMBO Rep. 2002 Sep;3(9):862-8. Epub 2002 Aug 16.

48.

High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening.

Ma T, Vetrivel L, Yang H, Pedemonte N, Zegarra-Moran O, Galietta LJ, Verkman AS.

J Biol Chem. 2002 Oct 4;277(40):37235-41. Epub 2002 Aug 2.

49.

IL-4 is a potent modulator of ion transport in the human bronchial epithelium in vitro.

Galietta LJ, Pagesy P, Folli C, Caci E, Romio L, Costes B, Nicolis E, Cabrini G, Goossens M, Ravazzolo R, Zegarra-Moran O.

J Immunol. 2002 Jan 15;168(2):839-45.

50.

Activation of G551D CFTR channel with MPB-91: regulation by ATPase activity and phosphorylation.

Dérand R, Bulteau-Pignoux L, Mettey Y, Zegarra-Moran O, Howell LD, Randak C, Galietta LJ, Cohn JA, Norez C, Romio L, Vierfond JM, Joffre M, Becq F.

Am J Physiol Cell Physiol. 2001 Nov;281(5):C1657-66.

Supplemental Content

Loading ...
Support Center